Minneapolis, MN, United States of America

David Alan Perry

This inventor holds 1 USPTO granted patent. Top assignee: Parker Hughes Institute. Active years: 2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Alan Perry. Retrieved from https://idiyas.com/inventor/david-alan-perry

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: David Alan Perry: Innovator in Anti-Cancer Research

Introduction

David Alan Perry is a notable inventor based in Minneapolis, MN (US). He has made significant contributions to the field of cancer research through his innovative work on alkyl ketones. His research focuses on developing novel compounds that exhibit potent cytotoxic activity against various types of cancer cells.

Latest Patents

David Alan Perry holds a patent for "Alkyl ketones as potent anti-cancer agents." This patent describes novel alkyl ketone compounds that have shown effectiveness as anti-tumor agents, particularly against leukemia and breast tumor cells. His work in this area highlights the potential of these compounds in cancer treatment.

Career Highlights

Perry is associated with the Parker Hughes Institute, where he continues to advance his research in cancer therapeutics. His dedication to finding effective treatments for cancer has positioned him as a key figure in the scientific community.

Collaborations

David has collaborated with esteemed colleagues such as Fatih M Uckun and Rama Krishna Narla. These partnerships have further enriched his research and contributed to the development of innovative solutions in cancer treatment.

Conclusion

David Alan Perry's work exemplifies the impact of innovation in the fight against cancer. His research on alkyl ketones represents a promising avenue for developing effective anti-cancer agents.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…